K071745

1. 510(k) Summary

JUL 19 2007

Page 1 of 2

Submitter Information

A. Company Name: Baylis Medical Company Inc.

B. Company Address: 2645 Matheson Blvd. East
Mississauga, Ontario L4W 5S4
Canada

C. Company Phone: (905) 602-4875; ext 252

D. Company Facsimile: (905) 602-5671

E. Contact Person: Meghal Khakhar

F. Summary Prepared on: 22-June-2007

Device Identification

A. Device Trade Name: Baylis Pain Management Single-Use Probe

B. Device Common Name: Radiofrequency lesion probe

C. Classification Name: Probe, Radiofrequency lesion, 21 CFR 882.4725

D. Device Class: Class II

E. Device Code: GXI

Identification of Predicate Device

Predicate device is the Baylis Pain Management Probe, which is cleared under 510(k) Premarket Notification Number K002389.

Device Description

The Baylis Pain Management Single-Use Probe is a sterile, single-use device that delivers Radiofrequency (RF) energy.

Intended Use

The Baylis Pain Management Single-Use Probe will be used in conjunction with a Baylis Pain Management Connector Cable and the Baylis Pain Management Generator to create radiofrequency lesions in nervous tissue.

Substantial Equivalence

The indications for use of the Baylis Pain Management Single-Use Probe are identical to the Baylis Pain Management Probe. Both the probes in conjunction with the Radiofrequency Generator are used to create radiofrequency lesions in nervous tissue. The fundamental scientific technology of both these devices is also the same.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

JUL 19 2007

Baylis Medical Company, Inc.
% Meghal Khakhar, MBBS, CerRAP, RAC
Regulatory Affairs Manager
2645 Matheson Boulevard East
Mississauga Ontario, Canada L4W 5S4

Re: K071745
Trade/Device Name: Baylis Pain Management Single-Use Probe
Regulation Number: 21 CFR 882.4725
Regulation Name: Radiofrequency lesion probe
Regulatory Class: II
Product Code: GXI
Dated: June 22, 2007
Received: June 27, 2007

Dear Meghal Khakhar:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N. Melkerson
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

K071745

Indications for Use

K071745

510(k) Number (if known):

Device Name: Baylis Pain Management Single-Use Probe

Indications For Use:

Baylis Pain Management Single-Use Probe will be used in conjunction with a Baylis Pain Management Connector Cable and the Baylis Pain Management Generator to create radiofrequency lesions in nervous tissue.

Prescription Use X AND/OR Over-The-Counter Use _____
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of General, Restorative, and Neurological Devices

510(k) Number K071745